



# Common Drug Review

## *Pharmacoeconomic Review Report*

January 2014

<b>Drug</b>	somatropin (Genotropin) (0.15 mg to 0.3 mg per day)
<b>Indication</b>	Replacement of endogenous growth hormone in adults with growth hormone deficiency
<b>Listing request</b>	List in the same manner as other currently listed somatropin products
<b>Manufacturer</b>	Pfizer Canada Inc.

This report was prepared by the Canadian Agency for Drugs and Technologies in Health (CADTH). Through the Common Drug Review (CDR) process, CADTH undertakes reviews of drug submissions, resubmissions, and requests for advice, and provides formulary listing recommendations to all Canadian publicly funded federal, provincial, and territorial drug plans, with the exception of Quebec.

The report contains an evidence-based clinical and/or pharmacoeconomic drug review, based on published and unpublished material, including manufacturer submissions; studies identified through independent, systematic literature searches; and patient-group submissions. In accordance with [CDR Update — Issue 87](#), manufacturers may request that confidential information be redacted from the CDR Clinical and Pharmacoeconomic Review Reports.

The information in this report is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. The information in this report should not be used as a substitute for the application of clinical judgment with respect to the care of a particular patient or other professional judgment in any decision-making process, nor is it intended to replace professional medical advice. While CADTH has taken care in the preparation of this document to ensure that its contents are accurate, complete, and up-to-date as of the date of publication, CADTH does not make any guarantee to that effect. CADTH is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in the source documentation. CADTH is not responsible for any errors or omissions or injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the information in this document or in any of the source documentation.

This document is intended for use in the context of the Canadian health care system. Other health care systems are different; the issues and information related to the subject matter of this document may be different in other jurisdictions and, if used outside of Canada, it is at the user's risk. This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

CADTH takes sole responsibility for the final form and content of this document, subject to the limitations noted above. The statements and conclusions in this document are those of CADTH and not of its advisory committees and reviewers. The statements, conclusions, and views expressed herein do not necessarily represent the views of Health Canada or any Canadian provincial or territorial government. Production of this document is made possible by financial contributions from Health Canada and the governments of Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Northwest Territories, Nova Scotia, Nunavut, Prince Edward Island, Saskatchewan, and Yukon.

You are permitted to make copies of this document for non-commercial purposes, provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish, or redistribute any material from this document in any form or by any means without the prior written permission of CADTH.

Please contact CADTH's Vice-President of Corporate Services at [corporateservices@cadth.ca](mailto:corporateservices@cadth.ca) with any inquiries about this notice or other legal matters relating to CADTH's services.

## TABLE OF CONTENTS

ABBREVIATIONS .....	ii
SUMMARY .....	iii
REVIEW OF THE PHARMACOECONOMIC SUBMISSION .....	1
1. Introduction .....	1
2. Summary of Pharmacoeconomic Submission .....	3
3. Interpretations and Key Limitations .....	4
4. Issues for Consideration .....	5
5. Conclusions .....	5
APPENDIX 1: UTILIZATION ANALYSIS .....	6
REFERENCES .....	7
<b>Tables</b>	
Table 1: Cost Comparison Table for Genotropin for Adult Growth Hormone Deficiency .....	2
Table 2: Trial Results for Omnitrope versus Genotropin in Pediatric Growth Hormone–Deficient Patients .....	3
Table 3: Cost Comparison Based on Maximum Doses for the Treatment of Adult Growth Hormone Deficiency .....	4
Table 4: Manufacturer-Submitted Sensitivity Analysis Results for the Treatment of Adult Growth Hormone Deficiency .....	4
Table 5: CDR Analysis of Utilization for Genotropin .....	6

## **ABBREVIATIONS**

<b>CDR</b>	Common Drug Review
<b>GHD</b>	growth hormone deficiency

## **SUMMARY**

Somatropin (Genotropin) is available as an injection with multiple strengths (0.6 mg, 0.8 mg, 1.0 mg, 1.2 mg, 1.4 mg, 1.6 mg, 1.8 mg, and 2.0 mg syringes, and 5.3 mg and 12 mg pens). It is indicated in Canada for the treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency; GHD), growth failure in short children born small for gestational age who fail to achieve catch-up growth by two to four years or later, short stature associated with Turner syndrome in patients whose epiphyses are not closed, idiopathic short stature, and adults with GHD of adult or childhood-onset. The manufacturer is requesting listing for reimbursement for its use in adult patients with GHD. Similar clinical effectiveness for Genotropin versus comparators was assumed based on the results of one trial comparing Genotropin to Omnitrope for treatment of GHD in children.<sup>1</sup> There were no published indirect comparisons of these drugs. Based on the Common Drug Review calculations using a confidential price of \$ [REDACTED] per milligram, the daily cost of the maximum dose of Genotropin (\$ [REDACTED]; 0.15 mg to 1.33 mg per day) is less than that of Humatrope (\$49; 0.006 mg/kg to 0.0125 mg/kg per day), Nutropin (\$82; 0.042 mg/kg to 0.175 mg/kg per week), and Omnitrope (\$41; 0.15 mg to 1.33 mg per day), but higher than that of Saizen (\$38; 0.005 mg/kg to 0.01 mg/kg per day).

## REVIEW OF THE PHARMACOECONOMIC SUBMISSION

### 1. INTRODUCTION

Somatropin (Genotropin) is an injectable recombinant human growth hormone indicated in Canada for the treatment of children who have growth failure due to an inadequate secretion of endogenous growth hormone (growth hormone deficiency; GHD), growth failure in short children born small for gestational age and who fail to achieve catch-up growth by two to four years or later, short stature associated with Turner syndrome in patients whose epiphyses are not closed, idiopathic short stature, and adults with GHD of adult- or childhood-onset. This Common Drug Review (CDR) pharmacoeconomic report will review its use in adults with GHD. The recommended dose of Genotropin in adults is 0.15 mg to 0.3 mg per day up to a maximum of 1.33 mg per day. The manufacturer submitted a confidential price of \$ [REDACTED] per milligram.

#### 1.1 Cost Comparison Table

The comparator treatments presented in the table below have been deemed the appropriate comparators by clinical experts. Comparators may be recommended (appropriate) practice, versus actual practice. Comparators are not restricted to drugs, but may be devices or procedures. Costs are manufacturer list prices, unless otherwise specified.

TABLE 1: COST COMPARISON TABLE FOR GENOTROPIN FOR ADULT GROWTH HORMONE DEFICIENCY

Drug/ Comparator	Strength	Dosage Form	Price (\$)	Recommended Dose	Average Daily Drug Cost <sup>a</sup> (\$)	Average Annual Drug Cost (\$)
Genotropin <sup>b</sup>	5.3 mg 12 mg	Pen	█	Initial: 0.15 mg to 0.30 mg per day Max: 1.33 mg per day	Initial: █ – Max: █	█ – █ Max: █
	0.6 mg 0.8 mg 1.0 mg 1.2 mg 1.4 mg 1.6 mg 1.8 mg 2.0 mg	Syringe	█		Max: █	Max: █
Humatrope	5 mg 24 mg	Vial	233.35 999.99	0.006 mg/kg to 0.0125 mg/kg per day titrated to adverse effects and to maintain IGF-1 less than upper limit for age and gender	21 to 49	7,665 to 17,886
	6 mg 12 mg	Cartridge	280.02 560.04		24 to 49	8,585 to 17,886
Nutropin	10 mg	Vial	389.44	0.042 mg/kg to 0.175 mg/kg per week for patients younger than 35 years; maximum 0.0875 mg/kg per week for those older than 35 years	20 to 82	7,164 to 29,851
Nutropin AQ	10 mg	Cartridge	392.55		20 to 82	7,221 to 30,089
Drug/ Comparator	Strength	Dosage Form	Price (\$)	Recommended Dose	Average Daily Drug Cost <sup>a</sup> (\$)	Average Annual Drug Cost (\$)
Omnitrope	5 mg 10 mg	Vial	155.80 311.60	Initial: 0.15 mg to 0.30 mg per day Max: 1.33 mg per day	Initial: 5 to 9 Max: 41	Initial: 1,706 to 3,412 Max: 15,126
Saizen	3.33 mg 5 mg 8.8 mg	Vial	149.25 224.05 358.47	0.005 mg/kg to 0.01 mg/kg per day	17 to 38	6,245 to 13,742
	6 mg 12 mg 20 mg	Cartridge	268.83 537.66 896.10		18 to 38	6,869 to 13,737

IGF-1 = insulin-like growth factor-1.

Prices are from the Saskatchewan Formulary (accessed August 23, 2013), unless otherwise indicated, and do not include dispensing fees.

<sup>a</sup>Weight-based doses use the average adult weight of 84 kg reported by Kreitschmann-Andermahr et al. 2012.<sup>2</sup>

<sup>b</sup>Manufacturer’s confidential submitted price.

## 2. SUMMARY OF PHARMACOECONOMIC SUBMISSION

The manufacturer submitted a cost-minimization analysis<sup>3</sup> comparing Genotropin to the other somatotropin drugs available in Canada: Humatrope, Saizen, Nutropin, and Omnitrope. Norditropin, an additional somatotropin available in Canada, was not included in the analysis since the manufacturer was unable to identify any use of this product in both public and private drug plans across the country. Serostim, another somatotropin, was not included, as its sole indication in Canada is for treatment of HIV wasting associated with catabolism, weight loss, or cachexia.

Similar clinical effectiveness of Genotropin with comparators was assumed by the manufacturer based on the results of one trial comparing Genotropin to Omnitrope for treatment of GHD in children,<sup>4</sup> the results of which suggest that there is similar efficacy among the different somatotropin drugs (Table 2). No indirect comparisons were identified in the literature search. The analysis was conducted from the Canadian public-payer perspective.

**TABLE 2: TRIAL RESULTS FOR OMNITROPE VERSUS GENOTROPIN IN PEDIATRIC GROWTH HORMONE–DEFICIENT PATIENTS**

	Omnitrope	Genotropin	95% CI
Number of patients	44	45	
Height baseline, cm	113.3	109.3	
Height at 9 months, cm	121.9	117.7	–0.59 to 1.06

CI = confidence interval.

Source: Genotropin Manufacturer Pharmacoeconomic Submission (Table 1, page 16).<sup>1</sup>

Only drug acquisition costs of Genotropin were considered, and these were obtained from the IMS Delta PA database.<sup>1</sup> The manufacturer assumed similar health care resource utilization among all somatotropin products. For the drug costs, the manufacturer used the lowest cost per milligram for each product, regardless of the variation in drug formulation or administration system. For the base-case analysis, the products were compared based on the minimum and maximum dosage reported in each of the comparator's respective product monograph (Table 3). The manufacturer reported that the average daily cost of the maximum dose of Genotropin (\$██████) is lower than that of Humatrope (\$43), Nutropin (\$41), ██████████ Omnitrope (\$37), and higher than that of Saizen (\$33). At maximum doses, Genotropin would be cost-neutral or would produce cost savings versus Humatrope, Nutropin, and Omnitrope, but would incur additional costs of \$██████ per patient per year compared with Saizen (Table 3).



**TABLE 3: COST COMPARISON BASED ON MAXIMUM DOSES FOR THE TREATMENT OF ADULT GROWTH HORMONE DEFICIENCY**

Product	Genotropin	Humatrope	Nutropin	Saizen	Omnitrope
Maximum dose (mg per day <sup>a</sup> )	1.33	1.05	1.05	0.84	1.33
Daily cost	\$ [REDACTED]	\$43.46	\$40.89	\$33.22	\$37.11
Annual	\$ [REDACTED]	\$15,863	\$14,924	\$12,126	\$13,544
<b>Incremental annual cost (savings) compared with Genotropin</b>		<b>\$2,319</b>	<b>\$1,380</b>	<b>(\$1,418)</b>	[REDACTED]

Adapted from Genotropin Manufacturer Pharmacoeconomic Submission (Tables 4 and 8, pages 19 and 22).<sup>1</sup>

<sup>a</sup> Dosages for Humatrope, Saizen, and Nutropin are based on an average adult weight of 84 kg.<sup>2</sup>

The manufacturer conducted a sensitivity analysis using a maximum dose of 1.0 mg per day in accordance with the Canadian guidelines for the management of adult GHD.<sup>5</sup> The results suggested that the annual cost of Genotropin is lower than that of Humatrope, Nutropin, and Saizen, and [REDACTED] that of Omnitrope (Table 4).

**TABLE 4: MANUFACTURER-SUBMITTED SENSITIVITY ANALYSIS RESULTS FOR THE TREATMENT OF ADULT GROWTH HORMONE DEFICIENCY**

Product	Genotropin	Humatrope	Nutropin	Saizen	Omnitrope
<b>Average annual cost per patient<sup>a</sup></b>	\$ [REDACTED]	\$15,107	\$14,213	\$14,436	\$10,184

<sup>a</sup> Based on the maximum daily dose (1.0 mg per day) recommended by Ur et al. 2006.<sup>6</sup>

### 3. INTERPRETATIONS AND KEY LIMITATIONS

#### 3.1 Lack of Evidence to Support Equivalent Efficacy and Safety

Equivalent efficacy was assumed based on a single head-to-head trial comparing Genotropin to Omnitrope in pediatric patients with GHD.<sup>4</sup> However, there are no data to support this assumption in adult GHD patients. No indirect comparisons for Genotropin versus other somatotropin drugs were identified in a literature search carried out by CDR.

## **4. ISSUES FOR CONSIDERATION**

The manufacturer is requesting that Genotropin be listed for use in adult patients with GHD. Somatropin, available through other brand names and products, is indicated for additional conditions such as idiopathic short stature and short stature homeobox-containing gene deficiency, for children born small for gestational age and for children with growth failure due to chronic renal failure. The potential for off-label use of Genotropin can be associated with considerable costs to the drug plans. However, it should be noted that this possibility of off-label use is not unique to Genotropin and applies to the other somatropin products on the market in Canada.

A CDR analysis of potential utilization in adult GHD patients in Canada (APPENDIX 1: UTILIZATION ANALYSIS) suggested that Genotropin could be associated with cost savings of up to \$1,317,168 per year for public plans.

## **5. CONCLUSIONS**

Based on CDR calculations using a confidential price of \$ [REDACTED] per milligram, the daily cost of the maximum dose of Genotropin (\$ [REDACTED]; 0.15 mg to 1.33 mg per day) is less than that of Humatrope (\$49; 0.006 mg/kg to 0.0125 mg/kg per day), Nutropin (\$82; 0.042 mg/kg to 0.175 mg/kg per week), and Omnitrope (\$41; 0.15 mg to 1.33 mg per day), but higher than that of Saizen (\$38; 0.005 mg/kg to 0.01 mg/kg per day).

## APPENDIX 1: UTILIZATION ANALYSIS

The submitted price for Genotropin (\$ [REDACTED] per milligram) is lower than that of Humatrope (\$41.39 per milligram), which is the most widely reimbursed somatotropin in Canada (based on public plan data), with an approximate market share of 58% in 2012. A scenario analysis was conducted in which Genotropin was assumed to replace Humatrope. Based on available prevalence data<sup>5,6</sup> and Canadian population estimates by age and gender for 2012,<sup>7</sup> this scenario analysis assumed that 78.66% of all units reimbursed for Humatrope were used by adult patients with GHD. This analysis is based on public coverage of Humatrope (no private plans are included). For product costs, both available provincial drug prices and manufacturer-submitted average prices per milligram were used. The results in Table 5 indicate the potential annual cost savings to the drug plan if Genotropin replaced Humatrope.

**TABLE 5: CDR ANALYSIS OF UTILIZATION FOR GENOTROPIN**

Current Price <sup>a</sup> (\$/mg)	Scenario	Minimum Savings <sup>b,c</sup>	Maximum Savings <sup>b,c</sup>
\$ [REDACTED]	Genotropin replaces the most widely used somatotropin (Humatrope) <sup>d,e</sup>	\$921,346	\$1,317,168

<sup>a</sup> Manufacturer-submitted confidential price.

<sup>b</sup> Does not include markup or dispensing fees.

<sup>c</sup> Savings per year based on provincial and manufacturer-submitted drug prices.

<sup>d</sup> Based on somatotropin comparator with most units covered by the ODB in 2012, IMS Brogan PharmaStat.

<sup>e</sup> Assumes that 78.66% of patients receiving Humatrope were adults with GHD.

## REFERENCES

1. CDR submission binder: Genotropin (somatropin [rDNA] for injection). Company: Pfizer Canada Inc. [**CONFIDENTIAL** manufacturer's submission]. Kirkland (QC): Pfizer Canada Inc.; 2013 May.
2. Kreitschmann-Andermahr I, Siegel S, Francis F, Buchfelder M, Schneider HJ, Kann PH, et al. Variation of the baseline characteristics and treatment parameters over time: an analysis of 15 years of growth hormone replacement in adults in the German KIMS database. *Pituitary*. 2012 Dec;15 Suppl 1:S72-S80.
3. Pharmacoeconomic evaluation. In: CDR submission binder: Genotropin (somatropin [rDNA] for injection). Company: Pfizer Canada Inc. [**CONFIDENTIAL** manufacturer's submission]. Kirkland (QC): Pfizer Canada Inc.; 2013 May.
4. Romer T, Saenger P, Peter F, Walczak M, Le Bouc Y, Khan-Boluki J, et al. Seven years of safety and efficacy of the recombinant human growth hormone Omnitrope in the treatment of growth hormone deficient children: results of a phase III study. *Horm Res*. 2009;72(6):359-69.
5. Ur E, Serri O, Legg K, Murphy LJ, Ezzat S. Canadian guidelines for the management of adult growth hormone deficiency. *Clin Invest Med*. 2006 Apr;29(2):83-90.
6. Eledrisi MS. Growth hormone deficiency [Internet]. In: Medscape. New York: WebMD; 2013 Jun 5 [cited 2013 Sep 13]. Available from: <http://emedicine.medscape.com/article/120767>.
7. Table 3: Population estimates, age distribution and median age as of July 1, 2012, Canada, provinces and territories [Internet]. In: Canada's population estimates: age and sex, July 1, 2012. Ottawa: Statistics Canada; 2012 Sep 27 [cited 2013 Sep 13]. Available from: <http://www.statcan.gc.ca/daily-quotidien/120927/t120927b003-eng.htm>.